Imatinib in PDGFR positive malignant solitary fibrous tumour of the pleura
Abstract
Keywords
Full Text:
PDFReferences
Santambrogio L, Nosotti M, Palleschi A, et al. Solitary fibrous tumor of the pleura presenting with syncope episodes when coughing. World J Surg Oncol. 2008;6:86.
Hanau CA, Miettinen M. Solitary fibrous tumour: histological and immunohistochemical spectrum of benign and malignant variants presenting at different sites. Hum Pathol. 1995; 26(4):440-9.
de Perrot M, Fischer S, Brundler MA, et al. Solitary fibrous tumours of the pleura. Ann Thorac Surg. 2002; 74(1):285-93.
Kim HJ, Lee HK, Seo JJ, et al. MR imaging of solitary fibrous tumours in the head and neck. Korean J Radiol 2005;6(3):136-42.
Robinson LA. Solitary fibrous tumour of the pleura. Cancer Control. 2006;13(4):264-9.
De Pas T, Toffalorio F, Colombo P, et al. Brief report: activity of imatinib in a patient with platelet-derived-growth-factor receptor positive malignant solitary fibrous tumour of the pleura. J Thorac Oncol. 2008;3(8):938-41.
Park MS, Ravi V, Conley A, et al. The role of chemotherapy in advanced solitary fibrous tumours; a retrospective analysis. Clin Sarcoma Res. 2013;3(1):7.
Constantinidou A, Jones RL, Scurr M, et al. Systemic therapy in solitary fibrous tumour. Proceedings of the 15th Connective Tissue Oncologic Society Annual Meeting. Miami, Florida, USA; 2009.
Corless CL, Schroeder A, Griffith D, et al. PDGFRA mutations in gastrointestinal stromal tumours: frequency, spectrum and in vitro sensitivity to imatinib. J Clin Oncol. 2005;23(23):5357-64.
Stacchiotti S, Negri T, Palassini E, et al. Sunitinib malate and figitumumab in solitary fibrous tumor: patterns and molecular bases of tumor response. Mol Cancer Ther. 2010; 9(5):1286-97.
Park MS, Patel SR, Ludwig JA, et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumour. Cancer. 2011;117(21):4939-47.
DOI: http://dx.doi.org/10.14319/ijcto.41.16

This work is licensed under a Creative Commons Attribution 3.0 License.
International Journal of Cancer Therapy and Oncology (ISSN 2330-4049)
© International Journal of Cancer Therapy and Oncology (IJCTO)
To make sure that you can receive messages from us, please add the 'ijcto.org' domain to your e-mail 'safe list'. If you do not receive e-mail in your 'inbox', check your 'bulk mail' or 'junk mail' folders.